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Abbreviation list 28 
AKI: acute kidney injury 29 
ART: Arterial Revascularization Trial  30 
BMI: body mass index  31 
BITA: bilateral internal thoracic artery  32 
CK-MB: creatine kinase MB  33 
CVA: cerebrovascular accident  34 
COPD: chronic obstructive pulmonary disease  35 
LMD: left main disease  36 
LVEF: left ventricular ejection fraction 37 
MACCE: major cardiac and cerebrovascular events  38 
MI: myocardial infarction  39 
ONCAB: on-pump coronary artery bypass 40 
OPCAB: off-pump coronary artery bypass  41 
SITA: single internal thoracic artery  42 
PCI: percutaneous coronary intervention 43 
PSM: Propensity score matching 44 
RBC: red blood cell 45 
PVD: peripheral vascular disease  46 
SMD: standardized mean difference 47 
SVG: saphenous vein graft  48 
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Central message: Off-pump and on-pump coronary artery bypass grafting are comparable in 49 
terms of 5-year rate of death and major cardiac and cerebrovascular events.   50 
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Perspective statement: Some studies have reported increased adverse event rates with off-51 
pump when compared to on-pump coronary artery bypass. The present post-hoc analysis of the 52 
ART trial found no significant difference between off-pump and on-pump coronary surgery in 53 
the rate of death and major cardiac and cerebrovascular events.    54 
5 
 
Abstract 55 
Background: The long-term effects of (OPCAB) continue to be controversial as some studies 56 
have reported increased adverse event rates with OPCAB when compared to on-pump coronary 57 
artery bypass (ONCAB). The Arterial Revascularization Trial (ART) compared survival after 58 
bilateral versus single internal thoracic artery grafting. The choice of OPCAB versus ONCAB 59 
was based on surgeon’s discretion. We performed a post-hoc analysis of the ART to compare 60 
5-year outcomes with two strategies.  61 
Methods: Among 3102 patients enrolled in the ART, we selected 1260 patients who underwent 62 
OPCAB versus 1700 patients who underwent ONCAB with cardioplegic arrest for the preent 63 
comparison. Primary outcomes were 5-year mortality and incidence of major cardiac and 64 
cerebrovascular events (MACCE) including cardiovascular death, myocardial infarction, 65 
cerebrovascular accident and revascularization after index procedure. Propensity score 66 
matching selected 1260 pairs for final comparison. Stratified Cox models were used for 67 
treatment effect estimate.  68 
Results: Hospital mortality was comparable between OPCAB and ONCAB groups (12[1.0%] 69 
vs 15[1.2%]; P=0.7). Conversion rate to on pump during OPCAB was 29/1260 (2.3%). When 70 
compared to OPCAB not converted, OPCAB converted to on-pump presented a remarkably 71 
higher hospital mortality (10.3% vs 0.7%; P<0.001). At 5 years, mortality rate was 110(8.9%) 72 
vs. 102(8.3%) in the OPCAB and ONCAB groups respectively with no significant difference 73 
(hazard ratio, HR 1.14; 95% confidence interval, CI 0.86-1.52; P=0.35). Incidence of MACCE 74 
was 175(14.3) vs. 169 (13.8) in the in the OPCAB and ONCAB groups respectively with no 75 
significant difference (HR 1.05 [0.84-1.31; P=0.65). 76 
Conclusions: The present post-hoc ART analysis support the hypothesis that both OPCAB and 77 
ONCAB are equally effective and safe.  78 
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Despite the potential advantages of avoiding cardiopulmonary bypass, the postulated benefits 79 
of off-pump coronary artery bypass (OPCAB) in terms of perioperative mortality and 80 
morbidity including stroke were not realized in the majority of studies comparing the two 81 
strategies [1]. Furthermore, the long-term effects of OPCAB continue to be controversial. The 82 
increased technical complexity of OPCAB can result in less complete revascularization and 83 
reduced graft patency rates with some studies reporting increased adverse event rates with 84 
OPCAB when compared to on-pump coronary artery bypass (ONCAB) [2-5]. 85 
Two large randomized controlled trials (RCT) comparing OPCAB vs ONCABG have recently 86 
reported conflicting findings. The CABG Off or On Pump Revascularization Study 87 
(CORONARY) [6] has recently shown comparable 5 years results between the two techniques. 88 
However, CORONARY enrolled only higher risk patients and this aspect may limit the 89 
generalizability of the study findings. On the other hand, the Department of Veterans Affairs 90 
"Randomized On/Off Bypass" (ROOBY) Trial [7] has reported increased 5 years mortality 91 
with OPCAB. However, the ROOBY trial was criticized for the fact that the conversion rate to 92 
cardiopulmonary bypass was unacceptably high at 12 % and this brought some skepticism on 93 
the level of “off pump” experience of the surgeons involved in the study. 94 
Consequently, the question whether OPCAB increases the risk of adverse events over the 95 
longer term when compared to ONCAB continues. The Arterial Revascularization Trial (ART) 96 
is designed to compare 10-year survival after bilateral internal thoracic artery (BITA) versus 97 
single left internal thoracic artery (SITA) grafting and an interim report at 5 years has not 98 
shown any clear difference between the two groups [8]. In the ART, the choice of OPCAB 99 
versus ONCAB was based on surgeon’s discretion. We sought to get further insights into the 100 
comparison between the two strategies by performing a post-hoc analysis of the ART.  101 
Materials and Methods 102 
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The present study is a post-hoc retrospective analysis of 5 year outcomes of the ART trial. This 103 
research adheres to the principles set forth in the Declaration of Helsinki 104 
(http://www.wma.net/en/30publications/10policies/b3/index.html). In the ART, the choice of 105 
OPCAB versus ONCAB was based on surgeon’s discretion. OPCAB versus ONCAB strategy 106 
adopted was available for all patients enrolled. Among patients enrolled in the ART (n=3102) 107 
from 2004 to 2007, we excluded those who did not undergo surgery (n=23). In two cases, there 108 
was no information regarding the use of cardiopulmonary bypass. We also excluded patients 109 
who received on-pump beating heart surgery (n=19) and 95 patients who received cross clamp 110 
fibrillation.  The present analysis compared 1260 patients who underwent OPCAB versus 1700 111 
patients who underwent ONCAB with cardioplegic arrest. OPCAB cases requiring 112 
intraoperative conversion to on-pump were included in the OPCAB group in the primary 113 
analysis (Figure 1). A total of 156 surgeons were involved. For 134 patients (60 OPCAB, 74 114 
ONCAB) no information on participating surgeon was available. The total number of 115 
procedures performed by each surgeon and the choice between OPCAB vs. ONCAB presented 116 
a large variation with a large proportion of surgeons performing only few procedures 117 
(Supplementary Table 1). No information was available on individual surgeon practice pattern 118 
and OPCAB experience before they took part to the trial (i.e. number of OPCAB vs ONCAB 119 
procedure performed per year).  120 
Trial design 121 
The ART has been approved by the institutional review board of all participating centres, and 122 
informed consent was obtained from each participant. The protocol for the ART has been 123 
published [9]. Briefly, the ART is a 2-arm, randomized multi centre trial conducted in 28 124 
hospitals in 7 countries, with patients being randomized equally to SITA or bilateral internal 125 
thoracic artery (BITA) grafts. Eligible patients were those with multivessel coronary artery 126 
disease undergoing coronary artery bypass grafting including urgent patients. Only emergency 127 
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patients (refractory myocardial ischemia/cardiogenic shock) and those requiring single grafts 128 
or redo surgery were excluded.  129 
Follow-up  130 
Questionnaires were sent to study participants by post at 12 months and then every year after 131 
surgery. No clinic visits were planned apart from the routine clinical 6-week post-operative 132 
visit. Participants were sent stamped addressed envelopes to improve the return rates of postal 133 
questionnaires. Study coordinators contacted participants by telephone to alert them to the 134 
questionnaire’s arrival and to ask them about medications, adverse events and health services 135 
resource use. Mean follow-up time for the present analysis was 4.9±1.0 years. Follow-up at 5 136 
years was completed for 2833/2960 (96%) patients.   137 
Study outcomes  138 
The two strategies were compared in terms of hospital outcomes and 5 years mortality and 139 
incidence of major cardiac and cerebrovascular events (MACCE) which included 140 
cardiovascular death, non-fatal myocardial infarction (MI), non-fatal cerebrovascular accident 141 
(CVA) and repeat revascularization. Treatment effect on individual MACCE components was 142 
also investigated. Adverse events were adjudicated blind to surgical procedure by a member of 143 
the Clinical Event Review Committee.  144 
Outcomes definitions 145 
Death was classified into cardiovascular and non-cardiovascular, where possible, using 146 
autopsy reports and death certificates. Congestive heart failure, arrhythmia or myocardial 147 
infarction, pulmonary embolus and dissection were considered cardiovascular causes of death.  148 
MI was diagnosed when two of the following three criteria were present: 1. Unequivocal ECG 149 
changes; 2. Elevation of cardiac enzyme(s) above twice the upper limit of normal or diagnostic 150 
troponin rises; 3. Chest pain typical for acute MI which lasted more than 20 minutes.  CVA 151 
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was defined as new neurological deficit evidenced by clinical signs of paresis, plegia or new 152 
cognitive dysfunction including any mental status alteration lasting more than 24 hours and/or 153 
evidence on CT or MRI scan of recent brain infarct (less than 6 months). Repeat 154 
revascularization was defined as coronary bypass surgery or percutaneous coronary 155 
intervention (PCI) performed after trial procedure. Acute kidney injury (AKI) defined as a 0.3 156 
mg/dl (≥26.5 mmol/l) creatinine increase from baseline within 48 hours of surgery.  157 
Statistical analysis  158 
Multiple imputation (m=3) was used to address missing data. Rubin’s method [10] was used 159 
to combine results from each of the imputed data sets (Amelia R package). Due to lack of 160 
randomization with regards to receiving OPCAB, a propensity score (PS) was generated for 161 
each patient from a multivariable logistic regression model based on 23 pre-treatment 162 
covariates as independent variables with OPCAB versus ONCAB as a binary dependent 163 
variable [10]. Pairs of patients were derived using greedy 1:1 matching with a calliper of width 164 
of 0.2 standard deviation of the logit of the PS (nonrandom R package). The quality of the 165 
match was assessed by comparing selected pre-treatment variables in propensity score–166 
matched patients using the standardized mean difference (SMD), with an absolute standardized 167 
difference of greater than 10% taken to represent meaningful covariate imbalance. [11]. 168 
McNemar's test and paired t-test was used to assess the statistical significance of the risk 169 
difference for hospital outcomes [12]. Cox regression models stratified on the matched pairs 170 
[12] were used to estimate the treatment effect on 5 years outcomes respectively. This approach 171 
accounts for the within-pair homogeneity by allowing the baseline hazard function to vary 172 
across matched sets. Risk competing framework was used to estimate the treatment effect on 173 
MACCE individual components. The Schoenfeld residuals test was used to test the 174 
independence between residuals and time and hence to test the proportional hazards assumption 175 
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in Cox models (survival R package). All p-values <0.05 were considered to indicate statistical 176 
significance.  177 
Due to the large number of participating surgeons and the marked variability of total number 178 
of procedures and OPCAB procedures performed individually, performing surgeons could not 179 
be included into PS model. To account for the potential influence of individual surgeon’s 180 
OPCAB experience, we classified each patient according to quartiles of total number of 181 
OPCAB procedures performed in the trial by the relative surgeon (0 [on-pump only], 1-5 [small 182 
OPCAB volume], 6-60 [moderate OPCAB volume], >60 [high OPCAB volume]) and 183 
outcomes in the matched sample were reported accordingly for descriptive purpose. Finally 184 
baseline characteristics and outcomes between OPCAB cases converted to on pump vs. not 185 
converted were also reported. All statistical analysis was performed using R Statistical 186 
Software (version 3.2.3; R Foundation for Statistical Computing, Vienna, Austria). 187 
Results 188 
Patient’s characteristics and operative data.  189 
OPCAB group was more likely to have higher creatinine and to receive BITA graft and was 190 
less likely to have treated hypertension, history of smoking and to receive saphenous vein graft. 191 
Total number of grafts per patients was comparable in the OPCAB and ONCAB groups 192 
(3.20±0.97 vs. 3.19±0.76; P=0.7). However, in the OPCAB group, the right coronary artery 193 
was less likely to be revascularized (62.1% vs 73.4%; P<0.001) whilst diagonal branches were 194 
more likely to be grafted in the OPCAB group (35.7% vs 29.2%; P<0.001). The two groups 195 
did not differ for rate of left anterior descending artery (98.1% vs 98.7%; P=0.24) and 196 
circumflex artery grafting (91.8% vs 92.6%; P=0.45).  197 
PSM selected 1260 matched pairs for final comparison (C statistic=0.71; Supplementary 198 
Figure 1). No residual imbalance was observed between matched groups (all SMD<10%) 199 
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(Table 1 and Supplementary Figure 2). After matching number of grafts in the OPCAB and 200 
ONCAB groups was comparable (3.20±0.97 vs. 3.17±0.87; P=0.35) 201 
Hospital outcomes 202 
Hospital outcomes comparisons before and after matching are reported in Table 2. In hospital 203 
mortality was low and comparable between OPCAB and ONCAB groups (1.0% vs 1.2% 204 
P=0.70). OPCAB was associated with a lower creatine kinase MB (CK-MB) peak at 24hrs 205 
postoperatively and a relative lower incidence of MI. However, the rate of intra-aortic balloon 206 
pump requirement was comparable between the two groups. OPCAB was associated with a 207 
lower rate of red blood cell (RCB) transfusion and a trend towards a lower incidence of sternal 208 
wound complication. OPCAB did not reduce the incidence of postoperative CVA, AKI and 209 
renal replacement therapy.  210 
5-year outcomes  211 
5-year outcomes comparisons before and after matching are reported in Table 3. 5-year 212 
mortality (Figure 2) and MACCE rates were comparable in the two groups. In terms of 213 
individual MACCE components, OPCAB was associated with a marginally non-significant 214 
1.1% absolute risk reduction in MI. CV death, CVA and Repeat revascularization rates were 215 
comparable between the two groups (Figure 3).  216 
Impact of intraoperative conversion to on-pump on outcomes   217 
Intraoperative conversion to on-pump occurred for 29 out of 1260 OPCAB (2.3%) procedures. 218 
Notably, distribution of risk factors between the OPCAB converted to on-pump group and 219 
OPCABG not converted group was similar (Supplementary Table 2). When compared to 220 
OPCAB not converted, OPCAB converted to on-pump presented a remarkably higher hospital 221 
mortality (10.3% vs 0.7%; P<0.001) and increased rate of hospital complications despite 222 
similar distribution of baseline risk factors. The trend towards poorer outcomes among OPCAB 223 
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cases converted to on-pump persisted at 5 years (Supplementary Table 3, Supplementary 224 
Figure 3).  225 
Surgeon OPCAB volume and outcomes  226 
A total of 95 surgeons performed on-pump only (951 patients); 33 surgeons performed between 227 
1 and 5 OPCAB procedures (531 patients; 62 OPCAB; 469 ONCAB); 25 surgeons performed 228 
between 6 and 60 OPCAB procedures (in total 779 patients; 530 OPCAB; 249 ONCAB); 229 
finally, 3 surgeons performed over 60 OPCAB procedures (in total 699 patients; 668 OPCAB; 230 
31 ONCAB)  231 
Baseline characteristics and outcomes in the matched OPCAB and ONCAB groups stratified 232 
per surgeon OPCAB volume are reported in Supplementary Table 4 and Supplementary Table 233 
5 and Supplementary Figure 4. OPCAB cases performed by “sporadic” OPCAB surgeons (1-234 
5 OPCAB procedures) presented a high rate of conversion (12.9%), a lower number of grafts 235 
performed (2.60±0.88) and a higher rate of operative mortality (4.8%) compared to other 236 
OPCAB subgroups despite risk factors distribution was similar.    237 
When OPCAB performed by 3 high volume OPCAB surgeons (>60) was compared to ONCAB 238 
by 95 “on-pump only” surgeons performing on-pump only we found similar 5-year overall 239 
mortality and MACCE rates.    240 
Among 28 ONCAB cases performed by 3 high OPCAB volume surgeons (>60), we observed 241 
a high hospital mortality rate (7.1%). However, this subgroup presented a higher prevalence of 242 
important risk factors including LVEF <30% and increased creatinine compared to other 243 
ONCAB subgroups suggesting that these 3 surgeons selectively used on-pump for high risk 244 
cases. 245 
Discussion  246 
The main finding of the present post-hoc analysis of the ART showed that when compared to 247 
ONCAB, OPCAB was associated with comparable number of grafts performed, a reduced 248 
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operative morbidity and comparable 5-year mortality and incidence of MACCE. Conversion 249 
rate to on-pump was relatively low (2.3%) but was associated with a remarkable increase in 250 
hospital mortality and morbidity and poorer 5-year outcomes.  251 
In the ART, over 50% of OPCAB procedures (668/1260) were performed by 3 surgeons only 252 
among 156 participating surgeons while 95 surgeons performed on-pump only. OPCAB 253 
performed by 3 high volume OPCAB surgeons was associated to hospital and 5-year mortality 254 
comparable to those observed after ONCAB performed by 95 “on-pump only” surgeons.  255 
We found that OPCAB performed by “sporadic” OPCAB surgeons (between 1 and 5 OPCAB 256 
procedure) was associated with a marked increase in conversion rate (12.9%), a lower number 257 
of graft performed and increased hospital mortality (4.8%).    258 
There is continued debate as to whether OPCAB may affect long-term outcomes due to a lower 259 
number of graft performed and subsequent effect of incomplete revascularization. Takagi et al. 260 
[2] pooled 5 randomized controlled trials and 17 adjusted observational studies that had 261 
reported long-term (≥5-year) all-cause mortality. In observational studies (102,820 patients) 262 
but not in randomized trials (1486 patients), OPCAB was associated with increased late 263 
mortality. 264 
Criticisms for observational studies comparing OPCAB and ONCAB include a possible bias 265 
toward including higher-risk patients in the OPCAB group [13]. Furthermore, incomplete 266 
revascularization in retrospective studies may be a surrogate marker for higher burden of 267 
comorbidities and per se might not be particularly relevant on patients’ outcome [14].  268 
The CORONARY trial [6] is a large trial (n=4502 patients) designed to compare the two 269 
strategies.  The final 5-year results showed similar outcomes with OPCAB and ONCAB. The 270 
difference between OPCAB and ONCAB in terms of number of grafts (3.0 vs. 3.2) and 271 
incidence of incomplete revascularization (11.8% vs. 10.0%) was only marginal. In the 272 
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CORONARY, each procedure was performed by a surgeon who had expertise in the specific 273 
type of surgery (completion of more than 100 cases of the specific technique either off-pump 274 
or on-pump). A limitation of the CORONARY is that only patients at higher risk were enrolled 275 
and this aspect might limit the generalizability of the study findings.    276 
In contrary, in the ROOBY trial [7], which enrolled 2203 patients, OPCAB has been recently 277 
reported to be associated with increased 5-year mortality (15.2% in the OPCAB group versus 278 
11.9% in the ONCAB group, relative risk, 1.28; 95% CI, 1.03 to 1.58; P=0.02). and MACCE 279 
rates (31.0% in the OPCAB group versus 27.1% in the ONCAB group (relative risk, 1.14; 95% 280 
CI, 1.00 to 1.30; P=0.046). This trial has also demonstrated that the patency rate of the off-281 
pump arm was lower than that of the on-pump arm on 12-month angiography [15]. Such 282 
findings can be partially explained on the basis that the 53 participating surgeons enrolled on 283 
average only eight patients per year during the study period and had unacceptably high 284 
conversion rates to on-pump surgery (12%) and incomplete revascularization (18%). 285 
Moreover, in 60% of the cases, a resident was the primary surgeon again raising concerns about 286 
the relative inexperience translating into poor graft patency. 287 
The present post-hoc analysis supports the equipoise between OPCAB and ONCAB in term of 288 
safety and efficacy. We found a trend towards a lower incidence of MI in the OPCAB group 289 
mainly related to early phase. It is well recognized that OPCAB is associated with a lower 290 
release of myocardial enzymes [16] but the clinical relevance of this observation remains 291 
unclear. Moreover, the definition of perioperative MI following myocardial revascularization 292 
remains controversial as well as its clinical implication [17].    293 
In the ART, over 50% of OPCAB procedures were performed by 3 high volume OPCAB 294 
surgeons only and this can partially explain the present findings. When OPCAB was performed 295 
by “sporadic” off-pump surgeons, this was associated with a lower number of grafts, higher 296 
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conversion rate and higher hospital mortality. This observation supports the central role of 297 
surgeon expertise in determining short and long-term results after off-pump.    298 
The unique technical challenges of OPCAB fuel the perception that adoption of this myocardial 299 
revascularization strategy may lead to poorer outcomes during each surgeon’s “learning curve” 300 
[18]. However, learning curve in off-pump CABG can be safely negotiated with appropriate 301 
patient selection, individualized grafting strategy, peer-to-peer training of the entire team, and 302 
graded clinical experience. Centers with established off-pump training programs have 303 
consistently shown that OPCAB can be safely and successfully taught to trainees without 304 
jeopardizing outcomes [19]. 305 
In the current era, increasing number of patients with high-risk profile is being referred for 306 
surgical myocardial revascularization and off-pump represents an attractive strategy to reduce 307 
operative morbidity especially in this subgroup as recently supported by a large meta-analysis 308 
of RCTs [20]. Therefore, OPCAB should remain in the armamentarium of cardiac surgeons 309 
(video 1). However, these superior outcomes in high-risk patients can only be achieved if off-310 
pump is offered to high- and low-risk patients alike and this further emphasizes the need for 311 
recognition of off-pump as a subspecialty with structured training program.  312 
The present analysis has intrinsic limitations. The main limitation is the retrospective analysis. 313 
The propensity technique can adjust only for measurable and included variables, and we cannot 314 
exclude a selection bias based on a nonmeasurable ‘‘eye-balling’’ including the quality of the 315 
targets. We had no information on specific surgeon off-pump expertise and we used total 316 
number of off-pump procedures performed in the ART as surrogate of off-pump expertise. 317 
However, the validity of this approach was further limited by the large variability of number 318 
of procedures performed per surgeon with a large proportion of surgeons performing less than 319 
5 procedures (67 over 156 surgeons). Moreover, we had no information on reasons for 320 
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preferring off-pump over on-pump and vice-versa across surgeon subgroups. Therefore, 321 
subgroup analysis based on surgeon OPCAB volume should be considered only as descriptive 322 
and hypothesis generating. Despite the present analysis did not show a significant difference 323 
in terms of mortality between the two strategies, there is a marginal trend towards an excess of 324 
cardiovascular deaths in the OPCAB group (4.1% vs. 3.1%) and it can be argued that the 325 
present analysis is underpowered to demonstrate a significant difference between the two 326 
groups. However, this difference is irrelevant when all-cause mortality is considered (8.9% vs 327 
8.3%). All-cause death is the most robust and unbiased index in cardiovascular research 328 
because no adjudication is required, thus avoiding inaccurate or biased documentation and 329 
inconsistency in endpoint definition.  330 
In conclusion, the present post-hoc ART analysis, found no significant difference at 5 years 331 
between the OPCAB and ONCAB in the rate of death, nonfatal stroke, nonfatal myocardial 332 
infarction or in the rate of subsequent revascularization procedures. Our results indicate that 333 
both procedures are equally effective and safe at least over the medium term. 334 
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Table 1. Baseline characteristics of patients undergoing OPCAB vs ONCAB  404 
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; SMD: 405 
standardized mean difference; PSM: propensity score matching; SBP: systolic blood pressure; 406 
DPB: diastolic blood pressure; COPD: chronic obstructive pulmonary disease; PVD: 407 
peripheral vascular disease; TIA: transient ischemic attack; CVA: cerebrovascular accident; 408 
MI: myocardial infarction; PCI: percutaneous coronary intervention; AF: atrial fibrillation; 409 
LVEF: left ventricular ejection fraction; LMD: left main disease; RA: radial artery BITA: 410 
Bilateral internal thoracic arteries, SVG: saphenous vein graft 411 
  412 
 OPCAB ONCAB 
unmatched 
SMD 
Pre-
PSM 
ONCAB 
matched 
SMD 
Post 
PSM 
n  1260 1700  1260  
Age (years) mean (sd)  64 (9) 64 (9) 1 64 (9) 1 
Female n(%) 180 (14.3) 240 (14.1) 0 180 (14.3) 0 
BMI mean (sd)  28.10 (4.10) 28.28 (3.87) 5 28.13 (3.87) 1 
SBP (mmHg) mean (sd)  133 (19) 131 (17) 9 132.30 (18) 2 
DBP (mmHg) mean (sd)  75 (11) 75 (11) 5 75.24 
(11.32) 
-1 
Creatinine (mmol/l) mean (sd)  100 (23) 94 (21) 26 97.75 
(21.58) 
9 
Treated Hypertension n(%) 943 (75) 1360 (80.0) -12 950 (75.4) -1 
Treated Hyperlipaemia n(%) 1176 (93.3) 1601 (94.2) -4 1178 (93.5) -1 
Diabetes n(%)    -6  1 
   No 980 (77.8) 1286 (75.6)  983 (78.0)  
   Insulin dependent  70 ( 5.6) 93 ( 5.5)  67 ( 5.3)  
   Non-insulin dependent   210 (16.7) 321 (18.9)  210 (16.7)  
Smoking n(%)    -14  -9 
   Current 180 (14.3) 242 (14.2)  149 (11.8)  
   Ex-smoker  664 (52.7) 999 (58.8)  723 (57.4)  
   Never   416 (33.0) 459 (27.0)  388 (30.8)  
COPD n(%) 29 ( 2.3) 43 ( 2.5) -2 28 ( 2.2) 1 
Asthma n(%) 63 ( 5.0) 65 ( 3.8) 6 59 ( 4.7) 2 
PVD n(%) 90 ( 7.1) 120 ( 7.1) 0 81 ( 6.4) 3 
TIA n(%) 40 ( 3.2) 60 ( 3.5) -2 40 ( 3.2) 0 
CVA n(%) 40 ( 3.2) 46 ( 2.7) 3 38 ( 3.0) 1 
MI n(%) 510 (40.5) 726 (42.7) - 5 513 (40.7) -1 
PCI n(%) 208 (16.5) 270 (15.9) 2 214 (17.0) -1 
Preop AF n(%) 19 ( 1.5) 24 ( 1.4) 1 16 ( 1.3) 2 
preop LVEF (%)    5  2 
     ≥50% (good)  950 (75.4) 1289 (75.8)  939 (74.5)  
     31-49% (moderate)  268 (21.3) 389 (22.9)  303 (24.0)  
     ≤30% (poor)  42 ( 3.3) 22 ( 1.3)  18 ( 1.4)  
LMD n(%) 282 (22.4) 356 (20.9) 4 277 (22.0) 1 
RA n(%) 240 (19.0) 381 (22.4) -8 252 (20.0) -2 
SVG n(%) 936 (74.3) 1344 (79.1) -11 956 (75.9) -4 
BITA n(%) 598 (47.5) 691 (40.6) 14 575 (45.6) 4 
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Table 2. Hospital outcomes of patients undergoing OPCAB vs ONCAB in the ART 413 
 
 
OPCAB ONCAB 
unmatched 
P-value* 
Pre-PSM  
ONCAB 
matched 
P-valueǂ 
Post-
PSM 
n  1260 1700  1260  
Death n(%)  12 (1.0) 18 (1.1) 0.92 15 (1.2) 0.70 
CVA n(%)  20 (1.6) 19 (1.1) 0.34 13 (1.0) 0.29 
Periop MI n(%)  10 (0.8) 40 (2.4) 0.002 32 (2.5) 0.001 
CK-MB 24h (U/L) mean (sd)  34 (179) 80 (125) 0.007 83 (139) 0.02 
IABP insertion n(%)  58 (4.6) 59 (3.5) 0.14 46 (3.7) 0.27 
Repeat Revascularization n(%)  8 (0.6) 7 (0.4) 0.56 7 (0.6) 1 
POAF n(%)  279 (22.1) 451 (26.5) 0.007 333 (26.4) 0.01 
Renal replacement therapy n(%)  72 (5.7) 79 (4.6) 0.22 64 (5.1) 0.54 
AKI n(%)  225 (17.9) 290 (17.1) 0.61 221 (17.5) 0.88 
Sternal wound complication n(%)  35 (2.8) 67 (3.9) 0.11 52 (4.1) 0.08 
Reexploration for bleeding n(%)  40 (3.2) 62 (3.6) 0.55 51 (4.0) 0.29 
RBC transfusion n(%) 165 (13.1) 280 (16.5) 0.01 207 (16.4) 0.02 
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PSM: 414 
propensity score matching; MI: myocardial infarction; CK-MB creatine kinase-MB; IABP: 415 
intra-aortic balloon pump; POAF: postoperative atrial fibrillation; AKI: acute kidney injury; 416 
RBC: red blood cell 417 
*Chi test or t-test 418 
ǂ  Mcnemar test or paired t-test 419 
 420 
  421 
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Table 3. 5-year outcomes of patients undergoing OPCAB vs ONCAB in the ART (expressed 422 
in number of events and cumulative incidence) 423 
 OPCAB ONCAB 
unmatched 
ONCAB  
Matched 
HR(95%CI) 
Post-PSM* 
P-value 
Post-
PSM* 
n  1260 1700 1260   
Mortality n(%) 110(8.9) 134(8.0) 102(8.3) 1.14[0.86-1.52] 0.35 
MACCE n(%) 175(14.3) 217(13.1) 169 (13.8) 1.05 [0.84-1.31] 0.65 
CV death n(%) 51(4.1) 47(2.8) 39(3.1) 1.39[0.90-2.13] 0.13 
MI n(%) 37(3.0) 61(3.6) 51(4.1) 0.66[0.43-1.02] 0.06 
CVA n(%) 41(3.3) 42(2.5) 32(2.6) 1.32[0.83-2.11] 0.24 
Revascularization n(%)  90(7.5) 108(6.4) 84(6.8) 1.09[0.80-1.49] 0.58 
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PSM: 424 
propensity score matching; MACCE: major cardiac and cerebrovascular event; CV: 425 
cardiovascular; MI: myocardial infarction; CVA: cerebrovascular accident 426 
*Cox model stratified for matched pairs  427 
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Table 4. Outcomes in patients undergoing OPCAB converted vs non-converted to on-pump 428 
 OPCAB 
converted to  
on-pump 
OPCAB not 
converted  
 
P-value 
N 29 1231  
In hospital outcomes*    
   Death n(%)  3 (10.3) 9 ( 0.7) <0.001 
   CVA n(%) 1 ( 3.4) 19 ( 1.5) 0.95 
   MI n(%) 0 ( 0.0) 10 ( 0.8) 1 
   CKMB at 24h (U/L) mean (sd)  182 (102) 31 (179) 0.15 
   IABP insertion n(%) 10 (34.5) 48 ( 3.9) <0.001 
  Repeat Revascularization n(%) 1 ( 3.4) 7 ( 0.6) 0.46 
  POAF n(%) 15 (51.7) 264 (21.4) <0.001 
  Renal replacement therapy n(%) 4 (13.8) 68 ( 5.5) 0.14 
  AKI n(%) 16 (55.2) 209 (17.0) <0.001 
  Sternal wound complication n(%) 1 ( 3.4) 34 ( 2.8) 1 
  Re-exploration for bleeding n(%) 3 (10.3) 37 ( 3.0) 0.09 
  RBC transfusion n(%) 17 (58.6) 148 (12.0) <0.001 
 
5-year outcomes ǂ    
   Mortality n(%) 4(13.8) 106(8.8) 0.3 
   MACCE n(%) 8(27.9) 167(14.0) 0.02 
   CV death n(%) 3(10) 48(4.0) 0.08 
   MI n(%) 2(6.9) 35(2.9) 0.18 
   CVA n(%) 1(3.4) 40(3.3) 0.92 
   Repeat Revascularization 4(13.8) 86(7.1) 0.12 
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PSM: 429 
propensity score matching; MI: myocardial infarction; IABP: intra-aortic balloon pump; 430 
POAF: postoperative atrial fibrillation; AKI: acute kidney injury; RBC: red blood cell; 431 
MACCE: major cardiac and cerebrovascular event; CV: cardiovascular; MI: myocardial 432 
infarction; CVA: cerebrovascular accident 433 
* Chi test or t-test 434 
ǂ Cox regression model   435 
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Table 5. Outcomes among OPCAB and matched ONCAB patients stratified for surgeon trial 436 
OPCAB volume  437 
 Matched ONCAB  OPCAB 
surgeon trial OPCAB 
volume quartiles 
0 1-5 6-60 >60 0 1-5 6-60 >60 
N of surgeons 95 33 25 3 95 33 25 3 
N of patients 688 340 204 28 - 62 530 668 
Hospital death n(%)  8 (1.2) 4 (1.2) 1 (0.5) 2 (7.1) - 3 (4.8) 3 (0.6) 6 (0.9) 
Conversion rate n(%) - - - - - 8(12.9) 14(2.6%) 7 (1.0%) 
N grafts mean(sd) 3.14 
(0.77) 
3.12 
(0.78) 
3.31 
(0.72) 
3.43 
(0.57) 
- 2.60 
(0.88) 
3.20 
(0.85) 
3.26 
(0.87) 
5-y Mortality n(%) 65(9.6) 22(6.7) 10(4.9) 5(17.9) - 5(8.2) 40 (7.8) 65(9.9) 
5-y MACCE n(%) 94(14.0) 44(13.4) 24(11.9) 7(25.7) - 9(14.9) 52(10.2) 114(17.5) 
5-y CV death n(%) 23(3.4) 8(2.4) 4(2.0) 28(14.3) - 3(4.8) 15(2.9) 33(5.0) 
5-y MI n(%) 23(3.4) 19(5.6) 8(3.9) 1(3.6) - 3(4.8) 9(1.7) 25(3.8) 
5-y CVA n(%) 16(2.4) 8(2.4) 6(3.0) 2(7.1) - 2(3.3) 16(3.1) 23(3.5) 
5-y Revascularization 
n(%) 
52(7.7) 16(4.9) 14(6.9) 28(7.1) - 3(5.0) 23(4.5) 64(9.7) 
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PSM: 438 
propensity score matching; MACCE: major cardiac and cerebrovascular event; CV: 439 
cardiovascular; MI: myocardial infarction; CVA: cerebrovascular accident 440 
  441 
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Supplementary Table 1. OPCAB, ONCAB and total number of cases performed according 442 
to individual surgeon  443 
 Surgeon# ONCAB OPCAB TOT 
(unknown) 74 60 134 
1 4 0 4 
2 0 1 1 
3 0 2 2 
4 0 2 2 
5 1 5 6 
6 1 0 1 
7 26 0 26 
8 18 0 18 
9 1 10 11 
10 0 1 1 
11 1 0 1 
12 16 0 16 
13 1 0 1 
14 1 1 2 
15 1 0 1 
16 4 0 4 
17 2 0 2 
18 4 0 4 
19 2 0 2 
20 37 0 37 
21 0 9 9 
22 8 2 10 
23 25 15 40 
24 28 1 29 
25 2 1 3 
26 1 0 1 
27 10 0 10 
28 1 0 1 
29 0 38 38 
30 21 0 21 
31 28 0 28 
32 20 0 20 
33 51 0 51 
34 9 0 9 
35 13 0 13 
36 0 15 15 
37 9 0 9 
38 17 0 17 
39 14 7 21 
40 10 0 10 
26 
 
41 63 17 80 
42 1 0 1 
43 5 0 5 
44 1 47 48 
45 18 1 19 
46 2 0 2 
47 3 0 3 
48 5 16 21 
49 2 0 2 
50 26 0 26 
51 0 6 6 
52 4 0 4 
53 1 0 1 
54 0 6 6 
55 20 1 21 
56 22 0 22 
57 4 43 47 
58 29 0 29 
59 37 0 37 
60 5 0 5 
61 0 10 10 
62 0 6 6 
63 53 4 57 
64 1 0 1 
65 15 0 15 
66 1 0 1 
67 5 0 5 
68 6 9 15 
69 3 0 3 
70 0 1 1 
71 6 0 6 
72 11 0 11 
73 1 0 1 
74 17 1 18 
75 25 0 25 
76 0 3 3 
77 32 0 32 
78 1 0 1 
79 2 47 49 
80 1 0 1 
81 26 0 26 
82 6 0 6 
83 1 1 2 
84 0 1 1 
85 0 48 48 
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86 1 77 78 
87 34 0 34 
88 37 0 37 
89 9 2 11 
90 1 0 1 
91 8 0 8 
92 3 0 3 
93 71 2 73 
94 7 2 9 
95 1 0 1 
96 13 0 13 
97 2 0 2 
98 1 34 35 
99 0 2 2 
100 1 0 1 
101 40 0 40 
102 1 0 1 
103 21 0 21 
104 27 8 35 
105 2 2 4 
106 31 2 33 
107 4 0 4 
108 6 12 18 
109 2 0 2 
110 11 20 31 
111 47 0 47 
112 0 3 3 
113 3 0 3 
114 1 0 1 
115 1 10 11 
116 1 0 1 
117 65 1 66 
118 1 0 1 
119 2 0 2 
120 18 5 23 
121 1 0 1 
122 26 5 31 
123 1 0 1 
124 1 8 9 
125 6 0 6 
126 1 0 1 
127 1 1 2 
128 6 0 6 
129 36 0 36 
130 5 1 6 
28 
 
131 2 18 20 
132 1 0 1 
133 7 0 7 
134 4 0 4 
135 1 0 1 
136 0 1 1 
137 0 412 412 
138 1 0 1 
139 1 0 1 
140 29 0 29 
141 0 2 2 
142 2 0 2 
143 5 11 16 
144 1 0 1 
145 1 0 1 
146 17 0 17 
147 9 1 10 
148 1 0 1 
149 19 0 19 
150 5 0 5 
151 1 0 1 
152 1 0 1 
153 76 1 77 
154 30 179 209 
155 6 0 6 
156 1 0 1 
 444 
  445 
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Supplementary Table 2. Baseline characteristics in patients undergoing OPCAB converted 446 
vs non-converted to on-pump 447 
 OPCAB not converted OPCAB converted 
to 
on-pump 
P* 
n  1231 29  
Age (years) mean (sd)  63.59 (9.06) 64.40 (9.77) 0.634 
Female n(%) 179 (14.5) 1 (3.4) 0.16 
BMI mean (sd)  28.10 (4.11) 28.15 (3.99) 0.95 
SBP (mmHg) mean (sd)  132.75 (19.11) 130.66 (17.94) 0.56 
DBP (mmHg) mean (sd)  75.40 (11.07) 72.48 (11.85) 0.16 
Creatinine (mmol/l) mean (sd)  99.68 (22.19) 107.76 (41.54) 0.06 
Treated Hypertension n(%) 919 (74.7) 24 ( 82.8) 0.44 
Treated Hyperlipaemia n(%) 1147 (93.2) 29 (100.0) 0.28 
Diabetes n(%)    0.78 
   No 959 (77.9) 21 (72.4)  
   Insulin dependent  68 ( 5.5) 2 (6.9)  
   Non-insulin dependent   204 (16.6) 6 (20.7)  
Smoking n(%)    0.02 
   Current 173 (14.1) 7 ( 24.1)  
   Ex-smoker  645 (52.4) 19 ( 65.5)  
   Never   413 (33.5) 3 ( 10.3)  
COPD n(%) 29 ( 2.4) 0 (  0.0) 0.83 
Asthma n(%) 58 ( 4.7) 5 ( 17.2) 0.009 
PVD n(%) 87 ( 7.1) 3 ( 10.3) 0.76 
TIA n(%) 40 ( 3.2) 0 (  0.0) 0.65 
CVA n(%) 40 ( 3.2) 0 (  0.0) 0.65 
MI n(%) 493 (40.0) 17 ( 58.6) 0.07 
PCI n(%) 199 (16.2) 9 ( 31.0) 0.06 
Preop AF n(%) 18 ( 1.5) 1 (  3.4) 0.92 
preop LVEF (%)    0.37 
     ≥50% (good)  927 (75.3) 23 ( 79.3)  
     31-49% (moderate)  264 (21.4) 4 ( 13.8)  
     ≤30% (poor)  40 ( 3.2) 2 (  6.9)  
LMD n(%) 276 (22.4) 6 ( 20.7) 1 
RA n(%) 231 (18.8) 9 ( 31.0) 0.15 
SVG n(%) 916 (74.4) 20 ( 69.0) 0.65 
BITA n(%) 582 (47.3) 16 ( 55.2) 0.51 
OPCAB: off-pump coronary artery bypass; SBP: systolic blood pressure; DPB: diastolic blood 448 
pressure; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; 449 
TIA: transient ischemic attack; CVA: cerebrovascular accident; MI: myocardial infarction; 450 
PCI: percutaneous coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection 451 
fraction; LMD: left main disease; RA: radial artery BITA: Bilateral internal thoracic arteries, 452 
SVG: saphenous vein graft 453 
*Chi test or t-test 454 
  455 
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Supplementary Table 3. Baseline characteristics of OPCAB and matched ONCAB patients 456 
stratified for surgeon trial OPCAB volume  457 
 Matched ONCAB  OPCAB 
surgeon trial 
OPCAB volume 
quartiles 
0 1-5 6-60 
 
>60 
 
 0 
 
1-5 
 
6-60 
 
>60 
 
N of surgeons 95 33 25 3  95 33 25 3 
N of patients  688 340 204 28  - 62 530 668 
Age (years) mean 
(sd)  
64(9) 62(9) 6(9) 66(9)  - 64(8) 62(8) 65(9) 
Female n(%) 93 
(13.5) 
55 
(16.2) 
28 
(13.7) 
4 
(14.3) 
 - 7 
(11.3) 
55 
(10.4) 
118 
(17.7) 
BMI mean (sd)  28(4) 28(4) 28(4) 29(4)  - 27(4) 28 (4) 28(4) 
SBP (mmHg) mean 
(sd)  
133 
(17) 
132 
(17) 
133 
(21) 
134 
(15) 
 - 132 
(17) 
131 
(19) 
134 
(20) 
DBP (mmHg) mean 
(sd)  
75.50 
(11.51) 
74.91 
(10.99) 
75.22 
(11.02) 
72.72 
(13.01) 
 - 75.11 
(8.85) 
76.51 
(10.96) 
74.42 
(11.30) 
Creatinine (mmol/l) 
mean (sd)  
98 
(23) 
95 (20) 101 
(19) 
111 
(17) 
 - 94 
(31) 
96 (22) 104 
(22) 
Treated 
Hypertension n(%) 
508 
(73.8) 
272 
(80.0) 
146 
(71.6) 
24 
(85.7) 
 - 53 
(85.5) 
389 
(73.4) 
501 
(75.0) 
Treated 
Hyperlipaemia n(%) 
629 
(91.4) 
323 
(95.0) 
201 
(98.5) 
25 
(89.3) 
 - 59 
(95.2) 
516 
(97.4) 
601 
(90.0) 
Diabetes n(%)       -    
   No 540 
(78.5) 
257 
(75.6) 
163 
(79.9) 
23 
(82.1) 
 - 49 
(79.0) 
415 
(78.3) 
516 
(77.2) 
   Insulin dependent  28 
(4.1) 
24 
(7.1) 
13 
(6.4) 
2 
(7.1) 
 - 2 
(3.2) 
25 
(4.7) 
43 
(6.4) 
   Non-insulin 
dependent   
120 
(17.4) 
59 
(17.4) 
28 
(13.7) 
3 
(10.7) 
 - 11 
(17.7) 
90 
(17.0) 
109 
(16.3) 
Smoking n(%)       -    
   Current 78 
(11.3) 
50 
(14.7) 
18 
(8.8) 
3 
(10.7) 
 - 8 
(12.9) 
85 
(16.0) 
87 
(13.0) 
   Ex-smoker  384 
(55.8) 
196 
(57.6) 
131 
(64.2) 
12 
(42.9) 
 - 37 
(59.7) 
264 
(49.8) 
363 
(54.3) 
   Never   226 
(32.8) 
94 
(27.6) 
55 
(27.0) 
13 
(46.4) 
 - 17 
(27.4) 
181 
(34.2) 
218 
(32.6) 
COPD n(%) 14 
(2.0) 
6 (1.8) 8 (3.9) 0 (0.0)  - 1 
(1.6) 
11 
(2.1) 
17 
(2.5) 
Asthma n(%) 35 
(5.1) 
11 
(3.2) 
11 
(5.4) 
2 
(7.1) 
 - 2 
(3.2) 
24 
(4.5) 
37 
(5.5) 
PVD n(%) 45 
(6.5) 
20 
(5.9) 
14 
(6.9) 
2 
(7.1) 
 - 2 
(3.2) 
29 
(5.5) 
59 
(8.8) 
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TIA n(%) 18 
(2.6) 
10 
(2.9) 
11 
(5.4) 
1 
(3.6) 
 - 1 
(1.6) 
19 
(3.6) 
20 
(3.0) 
CVA n(%) 28 
(4.1) 
7 (2.1) 3 (1.5) 0 
(0.0) 
 - 1 
(1.6) 
11 
(2.1) 
28 
(4.2) 
MI n(%) 272 
(39.5) 
148 
(43.5) 
81 
(39.7) 
12 
(42.9) 
 - 28 
(45.2) 
226 
(42.6) 
256 
(38.3) 
PCI n(%) 102 
(14.8) 
63 
(18.5) 
46 
(22.5) 
3 
(10.7) 
 - 17 
(27.4) 
135 
(25.5) 
56 
(8.4) 
Preop AF n(%) 8  
(1.2) 
3 
(0.9) 
5 
(2.5) 
0 
(0.0) 
 - 0 
(0.0) 
7 
(1.3) 
12 
(1.8) 
preop LVEF (%)       -    
   ≥50% (good)  516 
(75.0) 
253 
(74.4) 
153 
(75.0) 
17 
(60.7) 
 - 52 
(83.9) 
405 
(76.4) 
493 
(73.8) 
   31-49% (moderate)  162 
(23.5) 
85 
(25.0) 
48 
(23.5) 
8 
(28.6) 
 - 10 
(16.1) 
112 
(21.1) 
146 
(21.9) 
   ≤30% (poor)  10 
(1.5) 
2 (0.6) 3 (1.5) 3 
(10.7) 
 - 0 
(0.0) 
13 
(2.5) 
29 
(4.3) 
LMD n(%) 149 
(21.7) 
85 
(25.0) 
34 
(16.7) 
9 
(32.1) 
 - 6 
(9.7) 
101 
(19.1) 
175 
(26.2) 
RA n(%) 137 
(19.9) 
84 
(24.7) 
27 
(13.2) 
4 
(14.3) 
 - 9 
(14.5) 
90 
(17.0) 
141 
(21.1) 
SVG n(%) 524 
(76.2) 
232 
(68.2) 
175 
(85.8) 
25 
(89.3) 
 - 38 
(61.3) 
400 
(75.5) 
498 
(74.6) 
BITA n(%) 308 
(44.8) 
171 
(50.3) 
85 
(41.7) 
11 
(39.3) 
 - 23 
(37.1) 
252 
(47.5) 
323 
(48.4) 
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; SBP: 458 
systolic blood pressure; DPB: diastolic blood pressure; COPD: chronic obstructive pulmonary 459 
disease; PVD: peripheral vascular disease; TIA: transient ischemic attack; CVA: 460 
cerebrovascular accident; MI: myocardial infarction; PCI: percutaneous coronary intervention; 461 
AF: atrial fibrillation; LVEF: left ventricular ejection fraction; LMD: left main disease; RA: 462 
radial artery BITA: Bilateral internal thoracic arteries, SVG: saphenous vein graft  463 
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Figure Legend 464 
Central picture: 5-year cumulative incidence for mortality in the matched OPCAB and 465 
ONCAB groups. (OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary 466 
artery bypass) 467 
 468 
  469 
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Figure 1. Study flow chart for patient inclusion/exclusion (OPCAB: off-pump coronary artery 470 
bypass; ONCAB: on-pump coronary artery bypass) 471 
 472 
  473 
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Figure 2. 5-year cumulative incidence for mortality and major adverse cardiac and 474 
cerebrovascular events (MACCE) in the matched OPCAB and ONCAB groups. (OPCAB: off-475 
pump coronary artery bypass; ONCAB: on-pump coronary artery bypass) 476 
 477 
  478 
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Figure 3. 5-year cardiovascular(CV)-death, myocardial infarction (MI), cerebrovascular 479 
accident (CVA) and revascularization cumulative incidence in the OPCAB and ONCAB 480 
groups. (OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery 481 
bypass) 482 
 483 
  484 
36 
 
Supplementary Figure 1. Propensity score density before and after matching  485 
  486 
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Supplementary Figure 2. Changes in standardized mean difference for baseline 487 
characteristics between OPCAB and ONCAB before (red) and after matching (blue). (OPCAB: 488 
off-pump coronary artery bypass; SBP: systolic blood pressure; DPB: diastolic blood pressure; 489 
COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; TIA: 490 
transient ischemic attack; CVA: cerebrovascular accident; MI: myocardial infarction; PCI: 491 
percutaneous coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection 492 
fraction; LMD: left main disease; RA: radial artery BITA: Bilateral internal thoracic arteries, 493 
SVG: saphenous vein graft) 494 
  495 
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Supplementary Figure 3. 5-year cumulative incidence for mortality and major adverse cardiac 496 
and cerebrovascular events (MACCE) in the OPCAB group according to the incidence of 497 
conversion to on-pump. (OPCAB: off-pump coronary artery bypass) 498 
 499 
 500 
  501 
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Supplementary Figure 4. 5-year cumulative incidence for mortality and major adverse cardiac 502 
and cerebrovascular events (MACCE) in the OPCAB and ONCAB groups according to 503 
surgeon trial OPCAB volume (0=performing on-pump only; 1-5 low OPCAB volume; 6-60: 504 
moderate volume; >60 high volume) (OPCAB: off-pump coronary artery bypass; ONCAB: on-505 
pump coronary artery bypass) 506 
 507 
Video 1. Off-pump coronary artery bypass grafting at Bristol Heart Institute 508 
